Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Characterization of human UGT2A3 expression using a prepared specific antibody against UGT2A3.

Gotoh-Saito S, Abe T, Furukawa Y, Oda S, Yokoi T, Finel M, Hatakeyama M, Fukami T, Nakajima M.

Drug Metab Pharmacokinet. 2019 Aug;34(4):280-286. doi: 10.1016/j.dmpk.2019.05.001. Epub 2019 May 13.

PMID:
31262603
2.

Efflux transport of nicotine, cotinine and trans-3'-hydroxycotinine glucuronides by human hepatic transporters.

Järvinen E, Sjöstedt N, Koenderink JB, Kidron H, Finel M.

Basic Clin Pharmacol Toxicol. 2019 Jun 24. doi: 10.1111/bcpt.13281. [Epub ahead of print]

PMID:
31237077
3.

Inhibition of human carboxylesterases by magnolol: Kinetic analyses and mechanism.

Song YQ, Weng ZM, Dou TY, Finel M, Wang YQ, Ding LL, Jin Q, Wang DD, Fang SQ, Cao YF, Hou J, Ge GB.

Chem Biol Interact. 2019 Aug 1;308:339-349. doi: 10.1016/j.cbi.2019.06.003. Epub 2019 Jun 4.

PMID:
31170387
4.

Recent progress and challenges in screening and characterization of UGT1A1 inhibitors.

Lv X, Xia Y, Finel M, Wu J, Ge G, Yang L.

Acta Pharm Sin B. 2019 Mar;9(2):258-278. doi: 10.1016/j.apsb.2018.09.005. Epub 2018 Sep 14. Review.

5.

Data on biosynthesis of BPAF glucuronide, enzyme kinetics of BPAF glucuronidation, and molecular modeling.

Gramec Skledar D, Trontelj J, Troberg J, Tomašič T, Zega A, Finel M, Peterlin Mašič L.

Data Brief. 2018 Dec 17;22:977-986. doi: 10.1016/j.dib.2018.12.033. eCollection 2019 Feb.

6.

Case report by Toce and co-authors: Have all the reasons for poor morphine glucuronidation been addressed?

Finel M, Järvinen E.

Br J Clin Pharmacol. 2019 Apr;85(4):859-860. doi: 10.1111/bcp.13868. Epub 2019 Feb 8. No abstract available.

PMID:
30737810
7.

Metabolism of Scoparone in Experimental Animals and Humans.

Juvonen RO, Novák F, Emmanouilidou E, Auriola S, Timonen J, Heikkinen AT, Küblbeck J, Finel M, Raunio H.

Planta Med. 2019 Apr;85(6):453-464. doi: 10.1055/a-0835-2301. Epub 2019 Feb 8.

PMID:
30736072
8.

Inhibition of UGT1A1 by natural and synthetic flavonoids.

Liu XY, Lv X, Wang P, Ai CZ, Zhou QH, Finel M, Fan B, Cao YF, Tang H, Ge GB.

Int J Biol Macromol. 2019 Apr 1;126:653-661. doi: 10.1016/j.ijbiomac.2018.12.171. Epub 2018 Dec 28.

PMID:
30594625
9.

Endocrine activities and adipogenic effects of bisphenol AF and its main metabolite.

Skledar DG, Carino A, Trontelj J, Troberg J, Distrutti E, Marchianò S, Tomašič T, Zega A, Finel M, Fiorucci S, Mašič LP.

Chemosphere. 2019 Jan;215:870-880. doi: 10.1016/j.chemosphere.2018.10.129. Epub 2018 Oct 18.

PMID:
30408883
10.

A Novel Pathogenic UGT1A1 Variant in a Sudanese Child with Type 1 Crigler-Najjar Syndrome.

Elfar W, Järvinen E, Ji W, Mosorin J, Sega AG, Iuga AC, Lobritto SJ, Konstantino M, Chan A, Finel M, Lakhani SA.

Drug Metab Dispos. 2019 Jan;47(1):45-48. doi: 10.1124/dmd.118.084368. Epub 2018 Nov 1.

PMID:
30385458
11.

Molecular Docking-Based Design and Development of a Highly Selective Probe Substrate for UDP-glucuronosyltransferase 1A10.

Juvonen RO, Rauhamäki S, Kortet S, Niinivehmas S, Troberg J, Petsalo A, Huuskonen J, Raunio H, Finel M, Pentikäinen OT.

Mol Pharm. 2018 Mar 5;15(3):923-933. doi: 10.1021/acs.molpharmaceut.7b00871. Epub 2018 Feb 15.

12.

Efflux transport of estrogen glucuronides by human MRP2, MRP3, MRP4 and BCRP.

Järvinen E, Deng F, Kidron H, Finel M.

J Steroid Biochem Mol Biol. 2018 Apr;178:99-107. doi: 10.1016/j.jsbmb.2017.11.007. Epub 2017 Nov 22.

PMID:
29175180
13.

Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions.

Kahma H, Filppula AM, Neuvonen M, Tarkiainen EK, Tornio A, Holmberg MT, Itkonen MK, Finel M, Neuvonen PJ, Niemi M, Backman JT.

Drug Metab Dispos. 2018 Feb;46(2):141-150. doi: 10.1124/dmd.117.078162. Epub 2017 Nov 14.

PMID:
29138287
14.

Selectivity in the Efflux of Glucuronides by Human Transporters: MRP4 Is Highly Active toward 4-Methylumbelliferone and 1-Naphthol Glucuronides, while MRP3 Exhibits Stereoselective Propranolol Glucuronide Transport.

Järvinen E, Troberg J, Kidron H, Finel M.

Mol Pharm. 2017 Oct 2;14(10):3299-3311. doi: 10.1021/acs.molpharmaceut.7b00366. Epub 2017 Sep 13.

PMID:
28850245
15.

Identification and characterization of human UDP-glucuronosyltransferases responsible for xanthotoxol glucuronidation.

He G, Troberg J, Lv X, Xia YL, Zhu LL, Ning J, Ge GB, Finel M, Yang L.

Xenobiotica. 2018 Feb;48(2):109-116. doi: 10.1080/00498254.2017.1283719. Epub 2017 Jul 25.

PMID:
28689454
16.

UGT1A10 Is a High Activity and Important Extrahepatic Enzyme: Why Has Its Role in Intestinal Glucuronidation Been Frequently Underestimated?

Troberg J, Järvinen E, Ge GB, Yang L, Finel M.

Mol Pharm. 2017 Sep 5;14(9):2875-2883. doi: 10.1021/acs.molpharmaceut.6b00852. Epub 2016 Dec 14.

PMID:
27966992
17.

Biosynthesis of Drug Glucuronide Metabolites in the Budding Yeast Saccharomyces cerevisiae.

Ikushiro S, Nishikawa M, Masuyama Y, Shouji T, Fujii M, Hamada M, Nakajima N, Finel M, Yasuda K, Kamakura M, Sakaki T.

Mol Pharm. 2016 Jul 5;13(7):2274-82. doi: 10.1021/acs.molpharmaceut.5b00954. Epub 2016 Jun 8.

PMID:
27241161
18.

Influence of metabolism on endocrine activities of bisphenol S.

Skledar DG, Schmidt J, Fic A, Klopčič I, Trontelj J, Dolenc MS, Finel M, Mašič LP.

Chemosphere. 2016 Aug;157:152-9. doi: 10.1016/j.chemosphere.2016.05.027. Epub 2016 May 21.

PMID:
27213244
19.

Bisphenol-A glucuronidation in human liver and breast: identification of UDP-glucuronosyltransferases (UGTs) and influence of genetic polymorphisms.

Street CM, Zhu Z, Finel M, Court MH.

Xenobiotica. 2017 Jan;47(1):1-10. doi: 10.3109/00498254.2016.1156784. Epub 2016 Mar 21.

20.

The Polymorphic Variant P24T of UDP-Glucuronosyltransferase 1A4 and Its Unusual Consequences.

Troberg J, Finel M.

Drug Metab Dispos. 2015 Nov;43(11):1769-72. doi: 10.1124/dmd.115.065680. Epub 2015 Sep 1.

PMID:
26329791
21.

Glucuronidation of estrone and 16α-hydroxyestrone by human UGT enzymes: The key roles of UGT1A10 and UGT2B7.

Kallionpää RA, Järvinen E, Finel M.

J Steroid Biochem Mol Biol. 2015 Nov;154:104-11. doi: 10.1016/j.jsbmb.2015.07.013. Epub 2015 Jul 26.

PMID:
26220143
22.

An optimized ratiometric fluorescent probe for sensing human UDP-glucuronosyltransferase 1A1 and its biological applications.

Lv X, Ge GB, Feng L, Troberg J, Hu LH, Hou J, Cheng HL, Wang P, Liu ZM, Finel M, Cui JN, Yang L.

Biosens Bioelectron. 2015 Oct 15;72:261-7. doi: 10.1016/j.bios.2015.05.003. Epub 2015 May 8.

PMID:
25988789
23.

Exploring the structure-activity relationships of ABCC2 modulators using a screening approach.

Wissel G, Kudryavtsev P, Ghemtio L, Tammela P, Wipf P, Yliperttula M, Finel M, Urtti A, Kidron H, Xhaard H.

Bioorg Med Chem. 2015 Jul 1;23(13):3513-25. doi: 10.1016/j.bmc.2015.04.029. Epub 2015 Apr 17.

24.

Differences in the glucuronidation of bisphenols F and S between two homologous human UGT enzymes, 1A9 and 1A10.

Gramec Skledar D, Troberg J, Lavdas J, Peterlin Mašič L, Finel M.

Xenobiotica. 2015;45(6):511-9. doi: 10.3109/00498254.2014.999140. Epub 2014 Dec 30.

PMID:
25547628
25.

A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposure.

Fowler S, Kletzl H, Finel M, Manevski N, Schmid P, Tuerck D, Norcross RD, Hoener MC, Spleiss O, Iglesias VA.

J Pharmacol Exp Ther. 2015 Feb;352(2):358-67. doi: 10.1124/jpet.114.220194. Epub 2014 Dec 12.

PMID:
25503386
26.

Dog UDP-glucuronosyltransferase enzymes of subfamily 1A: cloning, expression, and activity.

Troberg J, Järvinen E, Muniz M, Sneitz N, Mosorin J, Hagström M, Finel M.

Drug Metab Dispos. 2015 Jan;43(1):107-18. doi: 10.1124/dmd.114.059303. Epub 2014 Oct 9.

PMID:
25301937
27.

A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives.

Greer AK, Dates CR, Starlard-Davenport A, Edavana VK, Bratton SM, Dhakal IB, Finel M, Kadlubar SA, Radominska-Pandya A.

Drug Metab Dispos. 2014 Sep;42(9):1392-400. doi: 10.1124/dmd.114.058016. Epub 2014 Jun 10.

28.

SVM classification and CoMSIA modeling of UGT1A6 interacting molecules.

Ghemtio L, Soikkeli A, Yliperttula M, Hirvonen J, Finel M, Xhaard H.

J Chem Inf Model. 2014 Apr 28;54(4):1011-26. doi: 10.1021/ci400577a. Epub 2014 Mar 18.

PMID:
24588678
29.

Determination of Serotonin and Dopamine Metabolites in Human Brain Microdialysis and Cerebrospinal Fluid Samples by UPLC-MS/MS: Discovery of Intact Glucuronide and Sulfate Conjugates.

Suominen T, Uutela P, Ketola RA, Bergquist J, Hillered L, Finel M, Zhang H, Laakso A, Kostiainen R.

PLoS One. 2013 Jun 27;8(6):e68007. doi: 10.1371/journal.pone.0068007. Print 2013.

30.

The Human UDP-glucuronosyltransferase UGT2A1 and UGT2A2 enzymes are highly active in bile acid glucuronidation.

Perreault M, Gauthier-Landry L, Trottier J, Verreault M, Caron P, Finel M, Barbier O.

Drug Metab Dispos. 2013 Sep;41(9):1616-20. doi: 10.1124/dmd.113.052613. Epub 2013 Jun 11.

31.

Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4.

Kato Y, Izukawa T, Oda S, Fukami T, Finel M, Yokoi T, Nakajima M.

Drug Metab Dispos. 2013 Jul;41(7):1389-97. doi: 10.1124/dmd.113.051565. Epub 2013 Apr 23.

PMID:
23611809
32.

A high throughput assay for the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin by recombinant human UDP-glucuronosyltransferases and liver microsomes.

Rahikainen T, Häkkinen MR, Finel M, Pasanen M, Juvonen RO.

Xenobiotica. 2013 Oct;43(10):853-61. doi: 10.3109/00498254.2013.783724. Epub 2013 Apr 3.

PMID:
23551063
33.

Albumin stimulates the activity of the human UDP-glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the effects are enzyme and substrate dependent.

Manevski N, Troberg J, Svaluto-Moreolo P, Dziedzic K, Yli-Kauhaluoma J, Finel M.

PLoS One. 2013;8(1):e54767. doi: 10.1371/journal.pone.0054767. Epub 2013 Jan 23.

34.

Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.

Sneitz N, Vahermo M, Mosorin J, Laakkonen L, Poirier D, Finel M.

Drug Metab Dispos. 2013 Mar;41(3):582-91. doi: 10.1124/dmd.112.049072. Epub 2013 Jan 3.

PMID:
23288867
35.

UDP-glucuronic acid binds first and the aglycone substrate binds second to form a ternary complex in UGT1A9-catalyzed reactions, in both the presence and absence of bovine serum albumin.

Manevski N, Yli-Kauhaluoma J, Finel M.

Drug Metab Dispos. 2012 Nov;40(11):2192-203. doi: 10.1124/dmd.112.047746. Epub 2012 Aug 21.

PMID:
22912433
36.

Human UDP-glucuronosyltransferase expression in insect cells: ratio of active to inactive recombinant proteins and the effects of a C-terminal his-tag on glucuronidation kinetics.

Zhang H, Patana AS, Mackenzie PI, Ikushiro S, Goldman A, Finel M.

Drug Metab Dispos. 2012 Oct;40(10):1935-44. doi: 10.1124/dmd.112.046086. Epub 2012 Jul 10.

PMID:
22782802
37.

Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10.

Fedejko-Kap B, Bratton SM, Finel M, Radominska-Pandya A, Mazerska Z.

Drug Metab Dispos. 2012 Sep;40(9):1736-43. doi: 10.1124/dmd.112.045401. Epub 2012 Jun 1.

38.

Ezetimibe: A biomarker for efficacy of liver directed UGT1A1 gene therapy for inherited hyperbilirubinemia.

Montenegro-Miranda PS, Sneitz N, de Waart DR, Ten Bloemendaal L, Duijst S, de Knegt RJ, Beuers U, Finel M, Bosma PJ.

Biochim Biophys Acta. 2012 Aug;1822(8):1223-9. doi: 10.1016/j.bbadis.2012.04.013. Epub 2012 Apr 21.

39.

Impact of probe compound in MRP2 vesicular transport assays.

Kidron H, Wissel G, Manevski N, Häkli M, Ketola RA, Finel M, Yliperttula M, Xhaard H, Urtti A.

Eur J Pharm Sci. 2012 May 12;46(1-2):100-5. doi: 10.1016/j.ejps.2012.02.016. Epub 2012 Mar 3.

PMID:
22406294
40.

Highly variable pH effects on the interaction of diclofenac and indomethacin with human UDP-glucuronosyltransferases.

Zhang H, Soikkeli A, Tolonen A, Rousu T, Hirvonen J, Finel M.

Toxicol In Vitro. 2012 Dec;26(8):1286-93. doi: 10.1016/j.tiv.2012.01.005. Epub 2012 Jan 14.

PMID:
22265884
41.

Characterization of hepatic and intestinal glucuronidation of magnolol: application of the relative activity factor approach to decipher the contributions of multiple UDP-glucuronosyltransferase isoforms.

Zhu L, Ge G, Zhang H, Liu H, He G, Liang S, Zhang Y, Fang Z, Dong P, Finel M, Yang L.

Drug Metab Dispos. 2012 Mar;40(3):529-38. doi: 10.1124/dmd.111.042192. Epub 2011 Dec 16.

PMID:
22180045
42.

Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues.

Court MH, Zhang X, Ding X, Yee KK, Hesse LM, Finel M.

Xenobiotica. 2012 Mar;42(3):266-77. doi: 10.3109/00498254.2011.618954. Epub 2011 Oct 13.

PMID:
21995321
43.

Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases.

Bratton SM, Mosher CM, Khallouki F, Finel M, Court MH, Moran JH, Radominska-Pandya A.

J Pharmacol Exp Ther. 2012 Jan;340(1):46-55. doi: 10.1124/jpet.111.184721. Epub 2011 Oct 4.

44.

Glucuronidation of the steroid enantiomers ent-17β-estradiol, ent-androsterone and ent-etiocholanolone by the human UDP-glucuronosyltransferases.

Sneitz N, Krishnan K, Covey DF, Finel M.

J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):282-8. doi: 10.1016/j.jsbmb.2011.08.008. Epub 2011 Aug 27.

45.

Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9.

Manevski N, Moreolo PS, Yli-Kauhaluoma J, Finel M.

Drug Metab Dispos. 2011 Nov;39(11):2117-29. doi: 10.1124/dmd.111.041418. Epub 2011 Aug 19.

PMID:
21856742
46.

Phenylalanine 93 of the human UGT1A10 plays a major role in the interactions of the enzyme with estrogens.

Höglund C, Sneitz N, Radominska-Pandya A, Laakonen L, Finel M.

Steroids. 2011 Dec 11;76(13):1465-73. doi: 10.1016/j.steroids.2011.07.017. Epub 2011 Aug 9.

47.

Fluorescence-based high-throughput screening assay for drug interactions with UGT1A6.

Soikkeli A, Kurkela M, Hirvonen J, Yliperttula M, Finel M.

Assay Drug Dev Technol. 2011 Oct;9(5):496-502. doi: 10.1089/adt.2010.0349. Epub 2011 Mar 25.

PMID:
21438674
48.

N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.

Kaivosaari S, Finel M, Koskinen M.

Xenobiotica. 2011 Aug;41(8):652-69. doi: 10.3109/00498254.2011.563327. Epub 2011 Mar 24. Review.

PMID:
21434773
49.

Effects of cell differentiation and assay conditions on the UDP-glucuronosyltransferase activity in Caco-2 cells.

Zhang H, Tolonen A, Rousu T, Hirvonen J, Finel M.

Drug Metab Dispos. 2011 Mar;39(3):456-64. doi: 10.1124/dmd.110.036582. Epub 2010 Nov 23.

PMID:
21098645
50.

Glucuronidation of racemic O-desmethyltramadol, the active metabolite of tramadol.

Lehtonen P, Sten T, Aitio O, Kurkela M, Vuorensola K, Finel M, Kostiainen R.

Eur J Pharm Sci. 2010 Nov 20;41(3-4):523-30. doi: 10.1016/j.ejps.2010.08.005. Epub 2010 Aug 24.

PMID:
20797434

Supplemental Content

Support Center